Healthpeak (PEAK) Leases Phase II At The Shore At Sierra Point
Zacks Investment Research | Jan 13, 2020 08:55PM ET
Healthpeak Properties (NYSE:PEAK) recently announced a lease with a subsidiary of Johnson & Johnson (NYSE:JNJ) at The Shore at Sierra Point. The move will help the company fortify its long-term partnership with the Johnson & Johnson Family. It also reflects strong demand for the company’s life-science real estates.
Particularly, this long-term lease with Janssen BioPharma, Inc. is expected to start in January 2022, following completion of construction. The lease is for 60% of Phase II at The Shore at Sierra Point, though Janssen BioPharma enjoys expansion rights under the lease, which can be exercised during 2020.
Notably, the five-building campus — The Shore at Sierra Pointis — aggregates more than 620,000 square feet across 23 acres on the waterfront in the city of Brisbane, in the greater South San Francisco, California life-science cluster. The campus offers close proximity to South San Francisco, Highway 101, public transit, as well as a high concentration of research companies.
The Phase I of The Shore, which totals 222,000 square feet, is nearing completion and is fully pre-leased to two tenants. Construction is on for Phase II and III, and is expected to be accomplished in 2021 and 2022.
Specifically, Phase II comprises two Class A purpose-built life-science buildings in the larger campus. Moreover, the addition to Phase II will link the two buildings across three of the four floors, boosting connectivity and functionality. In total, Phase II will comprise around 298,000 square feet, marking a rise from the initial 266,000 square feet planned.
Healthpeak has made concerted efforts to reposition its portfolio over the past few years. As part of these, the company has recycled capital through non-core dispositions to its solid investment and development pipeline. The strategic expansion of its life-science and medical office building (MOB) portfolio footprint, and selective buyouts of high-quality senior housing assets in high barrier-to-entry markets has renewed the company’s growth opportunities.
Increasing life expectancy of the U.S. population and bio-pharma drug development growth opportunities have boosted the institutional life-science and medical-real estate market fundamentals. Amid these, Healthpeak has adopted a cluster strategy in three premier life-science epicenters — San Diego, San Francisco and Boston — aimed at assembling assets through acquisitions, developments and redevelopments. On the back of these, the company is gaining scale and is well poised to meet the growing demand of life-science tenants.
Healthpeak currently carries a Zacks Rank #3 (Hold). In the past six months, shares of this REIT have gained 9.3% compared with its Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.